Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERO NASDAQ:DCOY NASDAQ:GLMD NASDAQ:GRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.03-1.9%$0.03$0.02▼$26.99$975K0.21535,125 shs214,056 shsDCOYDecoy Therapeutics$4.52-6.2%$6.43$4.52▼$415.80$2.56M0.3811,148 shs10,970 shsGLMDGalmed Pharmaceuticals$0.66+10.6%$0.62$0.41▼$2.34$3.26M0.62139,817 shs1.11 million shsGRIGRI Bio$2.15-4.9%$2.43$2.09▼$80.36$3.27M-1.2241,134 shs36,577 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics-1.85%-17.45%-15.87%-30.26%-99.77%DCOYDecoy Therapeutics-6.22%-21.25%-27.10%-49.02%+451,999,900.00%GLMDGalmed Pharmaceuticals+10.62%+5.11%-7.12%+7.42%-49.73%GRIGRI Bio-4.87%-4.44%-11.89%-6.93%-94.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.03-1.9%$0.03$0.02▼$26.99$975K0.21535,125 shs214,056 shsDCOYDecoy Therapeutics$4.52-6.2%$6.43$4.52▼$415.80$2.56M0.3811,148 shs10,970 shsGLMDGalmed Pharmaceuticals$0.66+10.6%$0.62$0.41▼$2.34$3.26M0.62139,817 shs1.11 million shsGRIGRI Bio$2.15-4.9%$2.43$2.09▼$80.36$3.27M-1.2241,134 shs36,577 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics-1.85%-17.45%-15.87%-30.26%-99.77%DCOYDecoy Therapeutics-6.22%-21.25%-27.10%-49.02%+451,999,900.00%GLMDGalmed Pharmaceuticals+10.62%+5.11%-7.12%+7.42%-49.73%GRIGRI Bio-4.87%-4.44%-11.89%-6.93%-94.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEROCERo Therapeutics 1.67Reduce$45.00169,711.32% UpsideDCOYDecoy Therapeutics 2.00Hold$30.00563.72% UpsideGLMDGalmed Pharmaceuticals 1.00SellN/AN/AGRIGRI Bio 2.33Hold$1,008.0046,783.72% UpsideCurrent Analyst Ratings BreakdownLatest CERO, GRI, GLMD, and DCOY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/22/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026GLMDGalmed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GRIGRI Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/ADCOYDecoy TherapeuticsN/AN/AN/AN/A$7.29 per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$2.88 per shareN/AGRIGRI BioN/AN/AN/AN/A$4.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEROCERo Therapeutics-$8.30M-$102.61N/AN/AN/AN/AN/A-209.40%6/3/2026 (Estimated)DCOYDecoy Therapeutics-$12.52M-$106.90N/AN/AN/AN/A-395.42%-193.30%N/AGLMDGalmed Pharmaceuticals-$10.31M-$1.24N/AN/AN/AN/A-29.43%-26.00%5/20/2026 (Estimated)GRIGRI Bio-$11.96M-$235.02N/AN/AN/AN/A-289.01%-171.12%5/21/2026 (Estimated)Latest CERO, GRI, GLMD, and DCOY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/ACEROCERo Therapeutics-$0.8004N/AN/AN/AN/AN/A5/21/2026Q1 2026GRIGRI Bio-$3.74N/AN/AN/AN/AN/A5/13/2026Q1 2026GRIGRI Bio-$3.74-$1.61+$2.13-$1.61N/AN/A5/8/2026Q1 2026DCOYDecoy TherapeuticsN/A-$4.18N/A-$4.18N/AN/A3/31/2026Q4 2025DCOYDecoy TherapeuticsN/A$43.10N/A$43.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCEROCERo TherapeuticsN/AN/AN/AN/AN/ADCOYDecoy TherapeuticsN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AGRIGRI Bio$1.9188.84%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEROCERo TherapeuticsN/A0.560.56DCOYDecoy TherapeuticsN/A1.842.13GLMDGalmed PharmaceuticalsN/A6.556.55GRIGRI BioN/A3.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEROCERo Therapeutics29.64%DCOYDecoy Therapeutics11.88%GLMDGalmed Pharmaceuticals76.14%GRIGRI Bio33.95%Insider OwnershipCompanyInsider OwnershipCEROCERo Therapeutics0.36%DCOYDecoy Therapeutics0.30%GLMDGalmed Pharmaceuticals19.80%GRIGRI Bio8.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEROCERo Therapeutics836.79 million1.05 millionN/ADCOYDecoy Therapeutics20530,000530,000N/AGLMDGalmed Pharmaceuticals205.48 million4.39 millionNot OptionableGRIGRI Bio11.45 million1.32 millionNot OptionableCERO, GRI, GLMD, and DCOY HeadlinesRecent News About These CompaniesGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued ...May 14 at 2:53 PM | markets.businessinsider.comGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating PipelineMay 14 at 8:35 AM | globenewswire.comGRI Bio (GRI) Expected to Announce Quarterly Earnings on ThursdayMay 14 at 2:25 AM | americanbankingnews.comGRI Bio (GRI) price target decreased by 75.16% to 163.20April 9, 2026 | msn.comGRI Springs on UAE PatentApril 9, 2026 | baystreet.caGRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory ConditionsApril 8, 2026 | globenewswire.comGRI Bio, Inc. Discusses Positive Phase 2a Data in Idiopathic Pulmonary Fibrosis During Virtual Investor SegmentFebruary 17, 2026 | quiverquant.comQGRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” SegmentFebruary 17, 2026 | globenewswire.comGRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialFebruary 5, 2026 | globenewswire.comGRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent HighlightsFebruary 4, 2026 | finanznachrichten.deGRI Bio (GRI) price target increased by 2,700.00% to 656.88February 4, 2026 | msn.comGRI Bio, Inc. Reports Strong Cash Position and Positive Phase 2a Results for GRI-0621 in Pulmonary FibrosisFebruary 4, 2026 | quiverquant.comQGRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent HighlightsFebruary 4, 2026 | globenewswire.comGRI Bio Expands At-The-Market Equity Offering CapacityJanuary 30, 2026 | tipranks.comGRI Bio, Inc.: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPFJanuary 29, 2026 | finanznachrichten.deGRI Bio reports positive study results for chronic lung disease, but stock slumps 20% — what happened?January 29, 2026 | msn.comGRI Bio stock soars after gene data shows IPF drug targets disease driversJanuary 28, 2026 | in.investing.comGRI Bio, Inc. Reports Positive Phase 2a Results for GRI-0621 as Disease-Modifying Therapy in Idiopathic Pulmonary FibrosisJanuary 28, 2026 | quiverquant.comQGRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPFJanuary 28, 2026 | globenewswire.comGRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound StructuresJanuary 26, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines1 Stock Is Powering the AI Boom and the Next Farm SupercycleBy Jeffrey Neal Johnson | April 22, 2026Chipotle Stock Just Hit Bottom—Is a Breakout Next?By Thomas Hughes | April 30, 2026The USMCA Review Is Coming: 3 Border-Sensitive Stocks to WatchBy Chris Markoch | May 8, 2026Astera Labs: The Tollbooth for AI's Traffic JamBy Jeffrey Neal Johnson | April 23, 20263 Agriculture Stocks to Buy as Food Inflation Stays Elevated in 2026By Chris Markoch | April 20, 2026CERO, GRI, GLMD, and DCOY Company DescriptionsCERo Therapeutics NASDAQ:CERO$0.03 0.00 (-1.85%) As of 05/14/2026 03:55 PM EasternCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Decoy Therapeutics NASDAQ:DCOY$4.52 -0.30 (-6.22%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$4.53 +0.01 (+0.11%) As of 07:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Galmed Pharmaceuticals NASDAQ:GLMD$0.66 +0.06 (+10.62%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.61 -0.05 (-7.06%) As of 08:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.GRI Bio NASDAQ:GRI$2.15 -0.11 (-4.87%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.18 +0.04 (+1.63%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
